Oncopeptides AB (STO:ONCO), a Swedish biotech company focused on difficult-to-treat cancers, announced on Tuesday that the US Food and Drug Administration (FDA) has lifted the clinical hold on OPD5, its next-generation Peptide Drug Conjugate (PDC) therapy.
OPD5, a follow-on to Oncopeptides' flagship drug melflufen (branded Pepaxti in Europe), is designed to treat multiple myeloma with a potentially improved risk-benefit profile.
The company plans to advance OPD5 into clinical development, starting with the OP-502 study to assess its safety, tolerability and efficacy. Oncopeptides sees strong demand for PDC therapies in the United States and is exploring additional indications for OPD5 beyond multiple myeloma.
To support its next phase of development, including a Phase 1 study, the company is evaluating financing options such as strategic partnerships.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval